Statins tied to lower mortality in some NSCLC subtypes

  • Lung Cancer

  • von Kelli Whitlock Burton
  • Studien – kurz & knapp
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Statin use before and after lung cancer diagnosis was associated with significantly lower mortality for patients with squamous cell carcinoma (SCC) and adenocarcinoma, but not small cell lung cancer (SCLC).

Why this matters

  • Prior studies have not adequately emphasized the effects of statins on all lung cancer subtypes.

Study design

  • 19,974 patients with lung cancer from the Surveillance, Epidemiology, and End Results-Medicare database.
  • Funding: American Cancer Society; others.

Key results

  • Statin use at baseline was associated with significantly lower mortality in patients with SCC (HR, 0.89; 95% CI, 0.82-0.96) and adenocarcinoma (HR, 0.87; 95% CI, 0.82-0.94), but not with SCLC (HR, 1.05; 95% CI, 0.92-1.20).
  • Postdiagnostic long-term statin use was associated with significantly lower mortality in patients with SCC (HR, 0.68; 95% CI, 0.59-0.79) and adenocarcinoma (HR, 0.78; 95% CI, 0.68-0.89), but not SCLC (HR, 1.16; 95% CI, 0.93-1.43).
  • Atorvastatin and simvastatin were associated with lower mortality in SCC and adenocarcinoma at baseline and postdiagnosis.
  • Association of statin use and decreased mortality was only found in early-stage disease.
  • No statin was significantly associated with decreased mortality in SCLC, although there was a trend toward an increased mortality risk with long-term pravastatin use (HR, 1.8; 95% CI, 1.00-3.51).

Limitations

  • Retrospective study.